期刊文献+

两种方法对乳腺癌人类表皮生长因子受体2检测的一致性评价 被引量:1

Consistency study of two methods in detection of human epidermal growth factor receptor-2 in breast cancer
原文传递
导出
摘要 目的对比分析免疫组织化学法(immunohistochemistry,IHC)和荧光原位杂交法(fluorescence in situ hybridization,FISH)对乳腺癌人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)检测的一致性评价。方法选取2013―2018年入住安徽省某三级甲等医院并确诊患乳腺癌的患者组织,分别采用IHC及FISH两种方法检测HER-2,对比其结果的差异及联系。结果在选取的276例乳腺癌患者体内发现FISH法检测HER-2扩增与乳腺癌组织学分级相关。IHC法检测HER-2结果为3+的病例与同时做FISH检测结果为阳性扩增的符合率可以达到90%以上。当IHC为-/+和3+时,2种方法检测结果的一致性最好。而HER-2检测为2+的病人,与FISH检测方法相比,两者的符合率仅为67.9%。结论HER-2基因扩增与乳腺癌的恶性程度增高有关,IHC筛查HER-2检测结果为2+乳腺癌需加做FISH检测,对于乳腺癌患者的进一步诊疗具有指导意义。 Objective To evaluate the consistency of immunohistochemistry(IHC)and fluorescence in situ hybridization(FISH)for the detection of human epidermal growth factor receptor-2(HER-2)in breast cancer.Methods The patients who were diagnosed with breast cancer in a third-class A hospital in Anhui Province from 2013 to 2018 were selected.IHC and FISH were used to detect HER-2,and the differences and connections were compared.Results In the selected 276 breast cancer patients,FISH detection of HER-2 amplification was related to the histological grade of breast cancer.For patients with HER-2 of 3+detected by IHC,the positive amplification rate of FISH could reach higher than 90%.When IHC was-/+and 3+,the consistency of detection results between the two methods was the best.For patients with 2+in HER-2 test,compared with FISH test,the coincidence rate of IHC was only 67.9%.Conclusions HER-2 gene amplification is associated with increased malignancy of breast cancer,HER-2 screening results of 2+breast cancer by IHC requires additional FISH test,which is of guiding significance for the further diagnosis and treatment of patients.
作者 杨懿 孟刚 YANG Yi;MENG Gang(Department of Pathology,Anhui Medical University,Hefei 230032,China)
出处 《中华疾病控制杂志》 CAS CSCD 北大核心 2020年第8期981-984,共4页 Chinese Journal of Disease Control & Prevention
基金 安徽高校自然科学研究重点项目(KJ2017A826)。
关键词 乳腺癌 人类表皮生长因子受体2 免疫组织化学法 荧光原位杂交法 Breast cancer Human epidermal growth factor receptor 2(HER-2) Immunohistochemistry(IHC) Fluorescence in situ hybridization(FISH)
  • 相关文献

参考文献3

二级参考文献18

  • 1Carney WP,Neumann R,Lipton A,et al.Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.Clin Chem,2003,49(10):1579-1598.
  • 2Carney WP,Neumann R,Lipton A,et al.Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.Clin Breast Cancer,2004,5(2):105-116.
  • 3Muller V,Witzel I,Luck HJ,et al.Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.Breast Cancer Res Treat,2004,86(1):9-18.
  • 4Luftner D,Henschke P,Kafka A,et al.Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization,automation and timing.Int J Biol Markers,2004,19(1):1-13.
  • 5Muller V,Thomssen C,Karakas C,et al.Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.Int J Biol Markers,2003,18(1):13-20.
  • 6Esteva FJ,Valero V,Booser D,et al.Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.J Clin Oncol,2002,20(7):1800-1808.
  • 7Saghatchian M,Guepratte S,Hacene K,et al.Serum HER-2 extracellular domain:relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients.Int J Biol Markers,2004,19(1):14-22.
  • 8Pichon MF,Hacene K,Guepratte S,et al.Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.Clin Lab,2004,50(3-4):163-170.
  • 9Schippinger W,Regitnig P,Bauernhofer T,et al.The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.Oncol Rep,2004,11(6):1331-1336.
  • 10Kostler WJ,Schwab B,Singer CF,et al.Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.Clin Cancer Res,2004,10(5):1618-1624.

共引文献25

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部